Update of the Drug Resistance Mutations in HIV-1: 2005.
暂无分享,去创建一个
Amalio Telenti | Victoria A Johnson | Francoise Brun-Vezinet | Bonaventura Clotet | Brian Conway | Daniel R Kuritzkes | Deenan Pillay | Jonathan Schapiro | Douglas Richman | D. Richman | A. Telenti | V. Johnson | F. Brun-Vézinet | B. Clotet | D. Kuritzkes | D. Pillay | J. Schapiro | B. Conway | F. Brun-vezinet
[1] J. Fitzgibbon,et al. Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2',3'-dideoxycytidine , 1992, Antimicrobial Agents and Chemotherapy.
[2] D. Richman,et al. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. , 1989, Science.
[3] Colombe Chappey,et al. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. , 2003, The Journal of infectious diseases.
[4] B Clotet,et al. Changes in the rate of genotypic resistance to antiretroviral drugs in Spain. , 2001, AIDS.
[5] M. Hirsch,et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. , 2000, JAMA.
[6] Victoria A Johnson,et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] Lee Bacheler,et al. Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs , 2003, AIDS.
[8] G. Beall,et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. , 2002, The New England journal of medicine.
[9] Sandra Franco,et al. Molecular Determinants of Multi-nucleoside Analogue Resistance in HIV-1 Reverse Transcriptases Containing a Dipeptide Insertion in the Fingers Subdomain , 2004, Journal of Biological Chemistry.
[10] Ronald J Bosch,et al. Genetic correlates of efavirenz hypersusceptibility , 2004, AIDS.
[11] R. Harrigan,et al. Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies , 2000, AIDS.
[12] Francesca Ceccherini-Silberstein,et al. Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort. , 2004, The Journal of infectious diseases.